Image Description (1 Formula)
Felodipine Tablet, Film Coated
Product Images NDC 71335-2175
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Felodipine (NDC 71335-2175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Label (Lbl713352175)
The text is a description of a medication called Felodpine ER, represented by an orange round tablet labeled YSP;210. The medication has a strength of 5mg and needs to be stored at room temperature between 20-25°C (68-77°F). It is comparable to Plendil 5mg tablet, and a pack consists of 30 tablets that expire at an unknown date. The medication is manufactured by Yung Shin Pharmaceutical Ind. Co. The label on the package warns to keep all drugs out of reach of children.*
Table 1 (Table 1)
This text provides data on the mean reductions in blood pressure measured in millimeters of mercury (mmHg) for two different studies. The first study lasted 8 weeks and included groups of patients taking doses of 25mg, 5mg, and 10mg. The second study lasted 4 weeks and included groups taking 0mg (placebo) and 20mg doses. The response ratios, expressed as percentages, are also provided for both trough and peak measurements. The placebo response was subtracted from the data. Different numbers of patients were available for peak and trough measurements.*
Table 2 (Table 2)
This is a summary of the adverse events experienced by patients in controlled trials of Felodipine Extended-Release Tablets as monotherapy without regard to causality. The table lists the adverse events experienced by patients in different body systems, including body as a whole, cardiovascular, digestive, nervous, respiratory, and skin. The incidence of discontinuations is shown in parentheses. Percent of patients with adverse events are documented for each dose level- Placebo, 25mg, 5mg, and 10mg. Patients in the titration study might have been exposed to more than one dose level of Felodipine extended-release tablets.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
